Navigate Fool.com
Will RPTP beat
the market?
Community Rating: 2 Stars: Unattractive

8.66 -0.07 (-0.80%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $8.76
Previous Close $8.73
Daily Range $8.50 - $8.84
52-Week Range $7.12 - $17.72
Market Cap $542.3M
P/E Ratio -7.66
Dividend (Yield) $0.00 (0.0%)
Volume 292,061
Average Daily Volume 663,497
Current FY EPS -$0.70

How do you think RPTP
will perform against the market?

Top RPTP Bull/Bear Pitches


bassman87 (0)
Submitted November 22, 2010

Has a solid pipeline of products that should be advancing into phase 3 stage of FDA approval and beyond through the next 12 to 36 months. <br /><br />Most notable of all its products currently in pha … More

0 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted November 23, 2013

For most of 2013, Raptor defied the skeptics and more than doubled their share price after a post-PDUFA dip. Lately, however, the upward ascent has shown signs of strain with a crack all the way down … More

0 Replies Reply Report this Post

News & Commentary

Are Investors Wrong About Raptor Pharmaceuticals?

Short-sellers have pushed into Raptor Pharmaceuticals in a big way lately. Here's why.

Why Plug Power, Aeropostale, and Raptor Pharmaceuticals Tumbled Today

Most investors in the broader stock market focused on the Ukrainian situation, resulting in a modest selloff for major market benchmarks. But these three stocks fell much more sharply. Find out why.

Why Raptor Pharmaceuticals Corp. Shares Cratered

Raptor shares nosedive after the company reports its fourth-quarter results and offers up sales guidance for fiscal 2014. Is this dip a buying opportunity or a reason to stay away?

This Week in Biotech: Buyouts, an FDA Approval, and Clinical Data. Oh, My!

A $25 billion buyout, a long-awaited FDA approval, two positive clinical studies, and one biopharma losing 37% of its value, are this week's top biotech stories.

Why Raptor Pharmaceuticals Corp. Shares Clawed Higher

Raptor shares climbed after releasing interim data for its ongoing phase 2/3 trial for RP103, a treatment for Huntington's disease. Is it time to break out the pom-poms?

Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar

Today's movers in biotech.

Keep a Close Watch on Synta Pharmaceuticals Corp., Raptor Pharmaceuticals Corp. and AngioDynamics, I

Today's biotech movers.

Oppenheimer Thinks Raptor Shares Could Bite

Does this analyst make a good case about Raptor? Or is it just more noise from Wall Street?

1 Biotech Going International

What does this EU approval mean for Raptor?

Have These 4 Biotechs Peaked?

Valuation must be considered in biotechnology, and when using industry standards, should investors be scared of these five top industry stocks?

See More RPTP News...





Raptor Pharmaceutical Corp. (RPTP) Description

Raptor Pharmaceutical Corp is a development-stage biotechnology Company which is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics. Website: http://www.raptorpharma.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks